http://orcid.org/0000-0001-8642-846X
References
- Ondetti MA, Williams NJ, Sabo E, et al. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemistry. 1971;10:4033–4039.
- Peeters H. Protides of the biological fluids. Proceedings of the twentieth colloquium, Brugge, 1972. Oxford: Pergamon Press; 2014.
- Tsang AT, Dudgeon C, Yi L, et al. Adaptors suppress the KRAS-MYC oncogenic axis in human pancreatic cancer xenografts. Mol Cancer Ther. 2017;16:1445–1455.
- Bolhassani A, Jafarzade BS, Peptides M-G. In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides. Peptides. 2016;8750–63.
- Provoda CJ, Stier EM, Lee K-DD. Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin. J Biol Chem. 2003;278:35102–35108.
- Luo GF, Chen WH, Liu Y, et al. Multifunctional enveloped mesoporous silica nanoparticles for subcellular co-delivery of drug and therapeutic peptide. Sci Rep. 2014;4:6064.
- Ngwa VM, Axford DS, Healey AN. one N-S. A versatile cell-penetrating peptide-adaptor system for efficient delivery of molecular cargos to subcellular destinations. PloS one. 2017;12:e0178648.
- Pfister AB, Wood RC, Salas PJ, et al. Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling. J Cell Biochem. 2010;111:643–652.
- Ramsauer VP, Carraway CA, Salas PJ, et al. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells. J Biol Chem. 2003;278:30142–30147.
- Ramsauer VP, Pino V, Farooq A, et al. Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2. Mol Biol Cell. 2006;17:2931–2941.
- Yu D, Oncogene H-M. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 2000;19:6115–6121.
- Biotechniques S-P. The sequence manipulation suite: JavaScript programs for analyzing and formatting protein and DNA sequences. Biotechniques. 2000;28:1102–1104.
- Frankel AD, Cell P-C. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 1988;55:1189–1193.
- Zhao M. Research reviews W-R. Intracellular cargo delivery using tat peptide and derivatives. Med Res Rev. 2004;24:1–12.
- Rawlings ND, Barrett AJ. Twenty years of the MEROPS database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 2016;44:D343–D350.
- Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based human protein atlas. Nat Biotechnol. 2010;28:1248–1250.
- Sheng Z, Wu K, Carraway KL, Fregien N. Molecular cloning of the transmembrane component of the 13762 mammary adenocarcinoma sialomucin complex. A new member of the epidermal growth factor superfamily. J Biol Chem. 1992;267:16341–16346.
- Carraway KL, Rossi EA, Komatsu M, et al. An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling. J Biol Chem. 1999;274:5263–5266.
- Munro S, Cell H. A C-terminal signal prevents secretion of luminal ER proteins. Cell. 1987;48:899–907.
- Yarden Y, reviews Cancer P-G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012;12:553–563.
- Ma X, Gong N, Zhong L, et al. Future of nanotherapeutics: targeting the cellular sub-organelles. Biomaterials. 2016;97:10–21.
- Park YJ, Liang JF, Ko KS, et al. Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study. J Gene Med. 2003;5:700–711.
- Bexiga M, Simpson J. Human diseases associated with form and function of the Golgi complex. Int J Mol Sci. 2013;14:18670–18681.